News

The acquisition is part of an ongoing collaboration and option agreement signed by the two companies in November 2012. As part of the acquisition, MorphoSys now has lanthipeptide

As announced on 2 October, 2014 Prima has reached an agreement to acquire Immutep subject to obtaining shareholder approval at its AGM to increase its share placement capacity

The U.S. patent No. 8,778,899, was granted for "Methods of Inducing Regulated Pancreatic Hormone Production in Non-pancreatic Islet Tissues" and recognizes the pioneering work done by Dr. Sarah

The newly issued patents expand the already large intellectual property estate surrounding BMP-7, which include over 450 issues and pending patents, and extends important intellectual property in OA

The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness. Dr. Nicholas

Jean-Philippe Langevin, M.D., an expert in neurotrauma and a neurosurgeon at the Veterans Affairs Greater Los Angeles (VAGLA) medical center, will lead the study as Principal Investigator. The

The company also announced the establishment of its corporate headquarters in Cambridge, Massachusetts, where Patrick Anquetil, Ph.D., MBA and Mark Philip, Ph.D., MBA serve as chief executive officer

Ofev is a kinase inhibitor that blocks multiple pathways that may be involved in the scarring of lung tissue and these capsules will be available to patients within

Esbriet is an oral medicine and is believed to interfere with the production of transforming growth factor (TGF) beta, a small protein in the body involved in the